Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.

Namki Hong Sungjae Shin Seunghyun Lee Yumie Rhee

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)

Romosozumab could improve bone mass and bone quality, measured by TBS, in postmenopausal osteoporosis, particularly as a subsequent regimen in patients previously taking anti-resorptive agents.

Keyphrases

bone mineral density
postmenopausal women
body composition
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
quality improvement